Abstract
The introduction of the 5-HT1B/1D agonist sumatriptan in 1991 marked a significant advance in the management of migraine. Sumatriptan was the first migraine pharmacotherapy designed to selectively target the neurovascular origin of migraine pain. Sumatriptan was introduced in several formulations – injection, nasal spray, conventional tablet or suppository. The latest sumatriptan formulation, a fast-disintegrating/rapid-release oral tablet, has recently been introduced into clinical practice. Swallowed with liquid, this sumatriptan tablet was developed to disintegrate and disperse more efficiently in the gastrointestinal tract than the conventional tablet. This article reviews clinical data on the long-standing formulations, discusses recent findings on the new fast-disintegrating/ rapid-release tablet, and considers the clinical applications of each of the sumatriptan formulations in the management of migraine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
